Rybrevant
FDA Approves Rybrevant for NSCLC With EGFR Exon 19 Deletions or L858R Mutations
The FDA has approved amivantamab-vmjw (Rybrevant, Janssen Biotech) with carboplatin and pemetrexed for adult ...
SEPTEMBER 20, 2024
FDA Approves Lazcluze With Rybrevant for Non-Small Cell Lung Cancer
The FDA has approved lazertinib (Lazcluze, Janssen Biotech) in combination with amivantamab-vmjw (Rybrevant, ...
AUGUST 20, 2024
FDA Approves Rybrevant for EGFR Exon 20 Insertion-Mutated NSCLC Indications
The FDA approved amivantamab-vmjw (Rybrevant, Janssen Biotech) with carboplatin and pemetrexed for the first-line ...
MARCH 4, 2024
FDA Approves Rybrevant for Advanced NSCLC With EGFR Mutations
The FDA granted accelerated approval to amivantamab-vmjw (Rybrevant, Janssen Biotech) for the treatment of adults ...
MAY 25, 2021
Load more